ESH CLL 2022 | Drug sensitivity testing in CLL
Sigrid Skånland, PhD, Oslo University Hospital, Oslo, Norway, discusses the use of drug sensitivity testing in chronic lymphocytic leukemia (CLL), highlighting some results from patient cases. Dr Skånland discusses a case study where drug sensitivity testing of the patient’s CLL cells demonstrated sensitivity to proteasome inhibitors, which helped with guiding therapy. Dr Skånland then explains that there are ongoing clinical trials that suggest drug sensitivity testing may be used in the future treatment of hematological malignancies and how this may improve patient outcome. This interview took place during the 2nd ESH Translational Research Conference on Chronic Lymphocytic Leukemia (ESH CLL), 2022.
Transcript (edited for clarity)
The work we presented at ESH represents one patient case where we used functional drug sensitivity testing to guide personalized therapy. And we also just recently published another patient case where we used drug sensitivity to test therapy. So this was also a patient that had received several lines of therapy and used all available options. And when we performed drug sensitivity testing on his CLL cells, we found that they were very sensitive to proteasome inhibitors...
The work we presented at ESH represents one patient case where we used functional drug sensitivity testing to guide personalized therapy. And we also just recently published another patient case where we used drug sensitivity to test therapy. So this was also a patient that had received several lines of therapy and used all available options. And when we performed drug sensitivity testing on his CLL cells, we found that they were very sensitive to proteasome inhibitors. And this is a therapy that is not approved for CLL, but it’s approved for multiple myeloma. And based on this, we could use this therapy for this patient as well. And we found that he responded very well and he became, again very active and had a good life. So that was very encouraging to see and we hope that this is something that can be used and there are also ongoing clinical trials and reports from clinical trials that suggest that the drug sensitivity testing in hematological malignancies can improve treatment outcome.
Read more...
